First-line treatment of multiple myeloma in elderly patients: The GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective

Pellegrino Musto, Fiorella D'Auria, Giuseppe Pietrantuono, Luca Baldini, Sara Bringhen, Tommaso Caravita, Francesco Di Raimondo, Fortunato Morabito, Massimo Offidani, Maria Teresa Petrucci, Patrizia Tosi, Francesca Gay, Michele Cavo, Mario Boccadoro, Antonio Palumbo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a neoplastic disorder affecting elderly people. The treatment for all patients with MM was, for about 40 years, based on the combination of melphalan plus prednisone, with a very low rate of complete remissions and a survival that remained unacceptably low (about 36 months). Diverse factors, including comorbidity, performance status, decreased physiologic reserve, and potential undertreatment, contribute to these poor outcomes. Recently, however, the reduced treatment-related morbidity and mortality associated with autologous stem-cell transplantation and the availability of effective new drugs with acceptable toxicity, such as thalidomide, lenalidomide and bortezomib, have greatly modified the traditional treatment paradigms in older patients with MM, challenging, in some cases, the definition of elderly and rapidly transforming the traditional palliative treatments to a new global therapeutic strategy, with the final objective of significantly improving the quality and the duration of life for elderly people with this disease. In this review, we report updated data for the front-line treatment of MM in the elderly population, examining the role of new drugs combined with melphalan or their incorporation within more complex combinations, including other so-called conventional drugs such as (pegylated)-doxorubicin, cyclophosphamide, and dexamethasone. We also assess the role of autologous and allogeneic stem-cell transplantation with adjusted conditioning regimens in selected elderly patients.

Original languageEnglish
Pages (from-to)906-922
Number of pages17
JournalCurrent Drug Targets
Volume10
Issue number10
DOIs
Publication statusPublished - 2009

Fingerprint

Multiple Myeloma
Melphalan
Stem cells
Pharmaceutical Preparations
Stem Cell Transplantation
Thalidomide
Prednisone
Doxorubicin
Cyclophosphamide
Dexamethasone
Toxicity
Therapeutics
Availability
Palliative Care
Comorbidity
Quality of Life
Morbidity
Survival
Mortality
Population

Keywords

  • Autologous transplantation
  • Bendamustine
  • Bortezomib
  • Cyclophosphamide
  • Dexamethasone
  • Doxorubicin
  • Elderly
  • Lenalidomide
  • Myeloma
  • Reduced-intensity allogeneic transplantation
  • Thalidomide

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

First-line treatment of multiple myeloma in elderly patients : The GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective. / Musto, Pellegrino; D'Auria, Fiorella; Pietrantuono, Giuseppe; Baldini, Luca; Bringhen, Sara; Caravita, Tommaso; Di Raimondo, Francesco; Morabito, Fortunato; Offidani, Massimo; Petrucci, Maria Teresa; Tosi, Patrizia; Gay, Francesca; Cavo, Michele; Boccadoro, Mario; Palumbo, Antonio.

In: Current Drug Targets, Vol. 10, No. 10, 2009, p. 906-922.

Research output: Contribution to journalArticle

Musto, P, D'Auria, F, Pietrantuono, G, Baldini, L, Bringhen, S, Caravita, T, Di Raimondo, F, Morabito, F, Offidani, M, Petrucci, MT, Tosi, P, Gay, F, Cavo, M, Boccadoro, M & Palumbo, A 2009, 'First-line treatment of multiple myeloma in elderly patients: The GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective', Current Drug Targets, vol. 10, no. 10, pp. 906-922. https://doi.org/10.2174/138945009789577936
Musto, Pellegrino ; D'Auria, Fiorella ; Pietrantuono, Giuseppe ; Baldini, Luca ; Bringhen, Sara ; Caravita, Tommaso ; Di Raimondo, Francesco ; Morabito, Fortunato ; Offidani, Massimo ; Petrucci, Maria Teresa ; Tosi, Patrizia ; Gay, Francesca ; Cavo, Michele ; Boccadoro, Mario ; Palumbo, Antonio. / First-line treatment of multiple myeloma in elderly patients : The GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective. In: Current Drug Targets. 2009 ; Vol. 10, No. 10. pp. 906-922.
@article{71cebde3bbd740cfbf00d3bd38dd51e8,
title = "First-line treatment of multiple myeloma in elderly patients: The GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective",
abstract = "Multiple myeloma (MM) is a neoplastic disorder affecting elderly people. The treatment for all patients with MM was, for about 40 years, based on the combination of melphalan plus prednisone, with a very low rate of complete remissions and a survival that remained unacceptably low (about 36 months). Diverse factors, including comorbidity, performance status, decreased physiologic reserve, and potential undertreatment, contribute to these poor outcomes. Recently, however, the reduced treatment-related morbidity and mortality associated with autologous stem-cell transplantation and the availability of effective new drugs with acceptable toxicity, such as thalidomide, lenalidomide and bortezomib, have greatly modified the traditional treatment paradigms in older patients with MM, challenging, in some cases, the definition of elderly and rapidly transforming the traditional palliative treatments to a new global therapeutic strategy, with the final objective of significantly improving the quality and the duration of life for elderly people with this disease. In this review, we report updated data for the front-line treatment of MM in the elderly population, examining the role of new drugs combined with melphalan or their incorporation within more complex combinations, including other so-called conventional drugs such as (pegylated)-doxorubicin, cyclophosphamide, and dexamethasone. We also assess the role of autologous and allogeneic stem-cell transplantation with adjusted conditioning regimens in selected elderly patients.",
keywords = "Autologous transplantation, Bendamustine, Bortezomib, Cyclophosphamide, Dexamethasone, Doxorubicin, Elderly, Lenalidomide, Myeloma, Reduced-intensity allogeneic transplantation, Thalidomide",
author = "Pellegrino Musto and Fiorella D'Auria and Giuseppe Pietrantuono and Luca Baldini and Sara Bringhen and Tommaso Caravita and {Di Raimondo}, Francesco and Fortunato Morabito and Massimo Offidani and Petrucci, {Maria Teresa} and Patrizia Tosi and Francesca Gay and Michele Cavo and Mario Boccadoro and Antonio Palumbo",
year = "2009",
doi = "10.2174/138945009789577936",
language = "English",
volume = "10",
pages = "906--922",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - First-line treatment of multiple myeloma in elderly patients

T2 - The GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective

AU - Musto, Pellegrino

AU - D'Auria, Fiorella

AU - Pietrantuono, Giuseppe

AU - Baldini, Luca

AU - Bringhen, Sara

AU - Caravita, Tommaso

AU - Di Raimondo, Francesco

AU - Morabito, Fortunato

AU - Offidani, Massimo

AU - Petrucci, Maria Teresa

AU - Tosi, Patrizia

AU - Gay, Francesca

AU - Cavo, Michele

AU - Boccadoro, Mario

AU - Palumbo, Antonio

PY - 2009

Y1 - 2009

N2 - Multiple myeloma (MM) is a neoplastic disorder affecting elderly people. The treatment for all patients with MM was, for about 40 years, based on the combination of melphalan plus prednisone, with a very low rate of complete remissions and a survival that remained unacceptably low (about 36 months). Diverse factors, including comorbidity, performance status, decreased physiologic reserve, and potential undertreatment, contribute to these poor outcomes. Recently, however, the reduced treatment-related morbidity and mortality associated with autologous stem-cell transplantation and the availability of effective new drugs with acceptable toxicity, such as thalidomide, lenalidomide and bortezomib, have greatly modified the traditional treatment paradigms in older patients with MM, challenging, in some cases, the definition of elderly and rapidly transforming the traditional palliative treatments to a new global therapeutic strategy, with the final objective of significantly improving the quality and the duration of life for elderly people with this disease. In this review, we report updated data for the front-line treatment of MM in the elderly population, examining the role of new drugs combined with melphalan or their incorporation within more complex combinations, including other so-called conventional drugs such as (pegylated)-doxorubicin, cyclophosphamide, and dexamethasone. We also assess the role of autologous and allogeneic stem-cell transplantation with adjusted conditioning regimens in selected elderly patients.

AB - Multiple myeloma (MM) is a neoplastic disorder affecting elderly people. The treatment for all patients with MM was, for about 40 years, based on the combination of melphalan plus prednisone, with a very low rate of complete remissions and a survival that remained unacceptably low (about 36 months). Diverse factors, including comorbidity, performance status, decreased physiologic reserve, and potential undertreatment, contribute to these poor outcomes. Recently, however, the reduced treatment-related morbidity and mortality associated with autologous stem-cell transplantation and the availability of effective new drugs with acceptable toxicity, such as thalidomide, lenalidomide and bortezomib, have greatly modified the traditional treatment paradigms in older patients with MM, challenging, in some cases, the definition of elderly and rapidly transforming the traditional palliative treatments to a new global therapeutic strategy, with the final objective of significantly improving the quality and the duration of life for elderly people with this disease. In this review, we report updated data for the front-line treatment of MM in the elderly population, examining the role of new drugs combined with melphalan or their incorporation within more complex combinations, including other so-called conventional drugs such as (pegylated)-doxorubicin, cyclophosphamide, and dexamethasone. We also assess the role of autologous and allogeneic stem-cell transplantation with adjusted conditioning regimens in selected elderly patients.

KW - Autologous transplantation

KW - Bendamustine

KW - Bortezomib

KW - Cyclophosphamide

KW - Dexamethasone

KW - Doxorubicin

KW - Elderly

KW - Lenalidomide

KW - Myeloma

KW - Reduced-intensity allogeneic transplantation

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=70450209034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450209034&partnerID=8YFLogxK

U2 - 10.2174/138945009789577936

DO - 10.2174/138945009789577936

M3 - Article

C2 - 19663768

AN - SCOPUS:70450209034

VL - 10

SP - 906

EP - 922

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 10

ER -